Latest industry research report on Hormone Refractory Prostate Cancer Market. Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
A promising drug pipeline, evolving treatment patterns and augmented patient awareness are the factors that would largely drive the market growth. Further, untapped patient population in the Asia Pacific region would lead to a large uptake of these treatments.
Get Free Sample Report Of Hormone Refractory Prostate Cancer Market @ http://www.marketresearchstore.com/report/world-hormone-refractory-prostate-cancer-market-71675#RequestSample
On the other hand, premium pricing of HRPCA drugs, uncertain reimbursement policies and limited survival periods are likely to curtail the market growth.
Notably, physician’s reluctance towards adoption of these premium treatments would remain a key challenge for the leading innovators. However, the untapped non-metastatic CRPC market would open new avenues for the new and existing companies. Additionally, emerging economies with undiagnosed patient population and mounting prevalence would provide growth opportunities in future.
The market is expected to register substantial growth attributed to the strategies adopted by leading market players. One of the key strategies adopted is collaboration agreement. For instance, in 2009, Astellas Pharma Inc. entered into an agreement with Mediation, Inc. to co-develop and co-commercialize MDV3100 (now Xtandi) for the treatment of HRPCA.
Do Inquiry To Buy Report Of Hormone Refractory Prostate Cancer Market @ http://www.marketresearchstore.com/report/world-hormone-refractory-prostate-cancer-market-71675#InquiryForBuying
The Global HRPCA market segmentation is illustrated below:
HRPCA Market By Therapy Type
- Cytotoxic Agents
- Hormonal Therapy
- Radiation Therapy
HRPCA Market By Geography
- North America